Xeris Biopharma Holdings (XERS) Asset Utilization Ratio (2021 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Asset Utilization Ratio came in at 0.81 in Q1 2026, up 16.48% YoY from 0.7 in Q1 2025, and up 4.85% on a QoQ basis from 0.77 in Q4 2025.
Xeris Biopharma Holdings (XERS) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 6 years of Asset Utilization Ratio data on file, last reported at 0.81 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 16.48% year-over-year to 0.81 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.81 (up 16.48% YoY) and the FY2025 annual result came in at 0.83, up 31.32% from the prior year.
- Asset Utilization Ratio climbed to 0.81 in Q1 2026, from 0.77 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.81 in Q1 2026 to a low of 0.2 in Q1 2022.
- A 5-year average of 0.52 and a median of 0.52 in 2024 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio surged 84.37% — and 2026, when it rose 16.48%.
- Tracing XERS's Asset Utilization Ratio over 5 years: stood at 0.34 in 2022, then surged by 48.03% to 0.5 in 2023, then grew by 25.08% to 0.63 in 2024, then gained by 22.83% to 0.77 in 2025, then rose by 4.85% to 0.81 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.81 (Q1 2026), 0.77 (Q4 2025), and 0.76 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 0.43 |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 0.63 |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 0.47 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 0.45 |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.41 |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 0.66 |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 0.37 |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 0.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.83 |
| Mar 31, 2026 | 0.81 |
| Dec 31, 2025 | 0.77 |
| Sep 30, 2025 | 0.76 |
| Jun 30, 2025 | 0.76 |
| Mar 31, 2025 | 0.70 |
| Dec 31, 2024 | 0.63 |
| Sep 30, 2024 | 0.57 |
| Jun 30, 2024 | 0.54 |
| Mar 31, 2024 | 0.52 |
| Dec 31, 2023 | 0.50 |
| Sep 30, 2023 | 0.47 |
| Jun 30, 2023 | 0.41 |
| Mar 31, 2023 | 0.36 |
| Dec 31, 2022 | 0.34 |
| Sep 30, 2022 | 0.32 |
| Jun 30, 2022 | 0.24 |
| Mar 31, 2022 | 0.20 |
| Dec 31, 2021 | 0.23 |